Alice Galli

Dr. Alice Galli

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in medRxiv
Verified
Preprint
Open access
PDF file
APAndrea Pilotto
Andrea Pilotto
VQVirginia Quaresima
Virginia Quaresima
CTChiara Trasciatti
Chiara Trasciatti
CTChiara Tolassi
Chiara Tolassi
DBDiego Bertoli
Diego Bertoli
APAlessandro Padovani
Alessandro Padovani
Background Plasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer’s disease (AD). No studies have compared the clinical performance of p-tau217 as assessed by the fully automated Lumipulse and SIMOA ALZpath p-tau217. Aim To evaluate the diagnostic accuracy of Lumipulse and SIMOA plasma p-tau217 assays for AD. Methods The study included 392 participants, 162 with AD, 70 with other neurodegenerative diseases (NDD) with CSF biomarkers and 160 healthy controls. Plasma p-tau217 levels were measured using the Lumipulse and ALZpath SIMOA assays. The ability of p-tau217 assessed by both techniques to discriminate AD from NDD and controls was investigated using ROC analyses. Results Both techniques showed high internal consistency of p-tau217 with similar correlation with CSF p-tau181 levels. In head-to-head comparison, Lumipulse and SIMOA showed similar diagnostic accuracy for differentiating AD from NDD (area under the curve [AUC] 0.952, 95%CI 0.927–0.978 vs 0.955, 95%CI 0.928–0.982, respectively) and HC (AUC 0.938, 95%CI 0.910-0.966 and 0.937, 95% CI0.907-0.967 for both assays). Conclusions This study demonstrated the high precision and diagnostic accuracy of p-tau217 for the clinical diagnosis of Alzheimer’s disease using either fully automated or semi-automated techniques.

23 October 2024 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
APAndrea Pilotto
Andrea Pilotto
AGAlice Galli
Alice Galli
CZCinzia Zatti
Cinzia Zatti
FPFabio Placidi
Fabio Placidi
FIFrancesca Izzi
Francesca Izzi
CLClaudio Liguori
Claudio Liguori
Methods: This study assessed data from two cohorts of patients with alpha‐synucleinopathies (University of Brescia and University of Rome Tor‐Vergata cohorts). Consecutive participants with video‐polysomnography‐confirmed iRBD, Parkinson's disease (PD), dementia with Lewy bodies (DLB) and controls underwent neurological, clinical and 123I‐FP‐CIT SPECT imaging assessments. Individuals with iRBD were longitudinally monitored to collect clinical phenoconversion to PD or DLB. The main outcome was to identify whole brain 123 I‐FP‐CIT SPECT measures reflecting monoaminergic deficits in each clinical group as compared to controls.Results: The cohort (n = 184) included 45 patients with iRBD, 47 PD, 42 DLB and 50 age‐matched controls. Individuals with iRBD were categorized as RBD‐DAT− (n = 32) and RBD‐DAT+ (n = 13), according to nigrostriatal assessment used in clinical practice. Compared to controls, RBD‐DAT− showed an early involvement of the left insula, which increased in RBD‐DAT+, and was present in patients with Parkinson's disease and dementia with Lewy bodies. Longitudinal cox regression analyses revealed a higher risk of phenoconversion in individuals with iRBD and insular monoaminergic deficits [HR = 3.387; CI 95%: 1.18–10.27].Interpretation: In this study, altered insular monoaminergic binding in iRBD was associated with phenoconversion to DLB or PD. These findings may provide a helpful stratification approach for future pharmacological or non‐pharmacological interventions.

22 April 2026 in Sensors
Verified
Journal Article
Open access
PDF file
ARAndrea Rizzardi
Andrea Rizzardi
CZCinzia Zatti
Cinzia Zatti
AGAlice Galli
Alice Galli
MFMohsen Fallahi
Mohsen Fallahi
SBSofia Bonomelli
Sofia Bonomelli
APAndrea Pilotto
Andrea Pilotto
Introduction: Motor reserve (MR) has been hypothesized as a protective factor against age-related and pathological motor decline, potentially enhancing quality of life. This study aimed to investigate the influence of MR on motor performance, assessed via mobile health technology (MHT), in drug-naïve Parkinson’s disease (PD) patients. Methods: Consecutive drug-naïve PD patients and age-matched healthy controls (HC) underwent cognitive and motor assessments. Turning MHT parameters were extracted from the Timed Up and Go test (TUG) performed at self-selected and fast speeds. Participants were categorized into high- or low-MR groups based on the Motor Reserve Index questionnaire (MRIq). Results: Forty-five PD patients and forty healthy controls (HC) were enrolled. PD patients showed longer TUG durations and altered performance compared to HC. No differences were found between high and low motor reserve (MR) groups in demographics or clinical severity. However, high-MR patients exhibited shorter turn duration and higher angular velocities at both self-selected (p < 0.005) and fast speeds (p < 0.05). MR subdomains related to physical and care activities correlated with MHT turning metrics, unlike housework and leisure domains. Conclusions: the findings highlighted the relevance of MR on motor performances assessed by MHT in drug naïve PD, independently from motor severity.

26 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
VCViviana Cristillo
Viviana Cristillo
TMTommaso Merati
Tommaso Merati
CTChiara Tolassi
Chiara Tolassi
Alessandro RondinaAlessandro Rondina
Alessandro Rondina
VBValentina Bettonagli
Valentina Bettonagli
APAlessandro Padovani
Alessandro Padovani
BackgroundMultiple sclerosis (MS) is characterized by inflammatory demyelination, neuroaxonal injury and progressive neurodegeneration. The biological processes driving the disease are already active at clinical onset, yet comprehensive characterization of different molecular pathways at diagnosis remains limited. ObjectiveTo integrate high-sensitivity CSF biomarker profiling with clinical disability measures, MRI lesion burden, and microstructural diffusion metrics in normal-appearing white matter (NAWM) in treatmentnaïve new diagnosed Multiple Sclerosis patients.MethodsCSF samples were collected from 70 treatment-naïve newly diagnosed MS patients and 11 age- and sex-matched healthy controls. A CNS Disease Panel of 120 CSF biomarkers was quantified using ultra-sensitive NULISA technology. Differential expression analysis was performed using false discovery rate (FDR) correction. Multivariable linear regression models adjusted for age, sex, and ethnicity were used to evaluate associations with baseline Expanded Disability Status Scale (EDSS), short-term clinical change after high-dose corticosteroid therapy (ΔEDSS) and MRI white matter lesion volume. Partial correlation analyses were performed to assess associations between CSF and diffusion MRI measures in NAWM regions of interest.ResultsSeven biomarkers were significantly increased in MS compared with controls after FDR correction: REST, IL-16, CHI3L1, NEFL, ICAM-1, TREM2, and CHIT1. Correlation analysis demonstrated clustering among markers of glial and innate immune activation (CHI3L1, TREM2, CHIT1) and moderate associations between NFL and glial markers. REST was strongly correlated with IL16, suggesting early transcriptional and immune pathway interplay.In multivariable models, higher levels of glial activation markers were independently associated with greater baseline disability. CSF NFL levels correlated with white matter lesion burden and were significantly associated with diffusion abnormalities in NAWM, particularly in the genu of the corpus callosum, cingulum, and anterior corona radiata, indicating that neuroaxonal injury reflects both focal inflammatory activity and diffuse microstructural damage beyond visible lesions.DiscussionThis application of ultra-sensitive NULISA multiplex CSF profiling in treatment-naïve MS at diagnosis demonstrates that multiple immunological and neurodegenerative pathways are simultaneously active at disease onset and are associated with early disability and microstructural white matter damage. These findings support the concept that inflammatory and neurodegenerative processes occur in parallel early in MS and suggest that integrated CSF biomarker profiling may improve early disease characterization.ConclusionsMultiplex CSF proteomic profiling using NULISA identifies biologically meaningful biomarker signatures at MS disease onset. Integration of multiplex biomarkers with clinical and imaging measures may improve early disease stratification and support personalized therapeutic strategies.

25 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ATAndrea Toja
Andrea Toja
EREqrem Rusi
Eqrem Rusi
CTChiara Tolassi
Chiara Tolassi
AGAlice Galli
Alice Galli
CTChiara Trasciatti
Chiara Trasciatti
APAlessandro Padovani
Alessandro Padovani
Background: Plasma phosphorylated tau (p-tau) isoforms are established biomarkers of Alzheimer’s disease (AD), but whether their combined elevation reflects biological heterogeneity within AD remains unclear.Objective: To determine whether distinct plasma p-tau217, p-tau181, and p-tau231 profiles identify clinically and biologically meaningful severity strata within biologically confirmed AD.Methods: We included 106 patients with CSF-confirmed AD at the mild cognitive impairment or dementia stage. Participants underwent clinical assessment, CSF Aβ42 and tau biomarker measurement, and plasma assessment of p-tau217, p-tau181, p-tau231, Aβ42/Aβ40, GFAP, and NfL. Longitudinal MMSE data were available in 80 participants over a mean 2.6-year follow-up. Patients were classified using ROC-derived multi-isoform profiles and, separately, p-tau217 quintiles. Clinical and biological group differences and age- and sex-adjusted regression models were evaluated.Results: Multi-isoform profiling identified five profiles, ranging from all-intermediate p-tau isoforms to triple-high. Compared with the all-intermediate profile, profiles with broader p-tau isoform elevation showed higher CSF tau markers, higher plasma GFAP and NfL, and faster annualized MMSE decline. The triple-high profile showed worst cognitive performance and highest plasma biomarker burden. Complementary p-tau217 quintile stratification showed a parallel severity gradient, with higher quintiles associated with increased CSF tau markers, GFAP, NfL, and cognitive decline. Regression analyses supported p-tau217 as the strongest single-marker correlate, whereas p-tau231 contributed to NfL and CSF t-tau models.Conclusions: Multi-isoform plasma p-tau profiling identifies biologically distinct AD severity strata, consistent with a hierarchy of increasing tau phosphorylation burden. p-tau217 captures much of this continuum and remains the most robust single-marker correlate, whereas p-tau231 may provide complementary information on neurodegeneration-related biology.